Improved anticancer drugs and drug carriers are needed in combination therapies, such as hyperthermia-assisted chemotherapy.
Here, initiative from the relevant clinical professional societies and patients groups may be needed in combination with simplification and improvements of regulatory requirements, to enable timely implementation of highly beneficial developments to improve medicine and patient care.
It is becoming increasingly clear, that one simple marker is insufficient for improved diagnosis, and thus multiple makers that reflect different aspects of the pathophysiology and clinical phenotypes may most likely be needed in combination (Kraus et al., 2015; Karsdal et al., 2014; Henrotin et al., 2016).
This could indicate that several alleles are needed in combination to create the extreme height observed in B73.
Alternatively, other genes outside the APA locus may be needed in combination with arcelin for resistance to be expressed.
This emphasizes that targeted therapies, potentially specific for each subtype, are needed in combination with improved methods for early detection.
Interestingly, a lower concentration of 5-FU was needed in combination with curcumin to inhibit the proliferation and viability of HCT116R cells.
Multi-faceted, patient-tailored methods of treatment are needed, in combination with improvement of adherence, i.e. disease-management programmes such as collaborative care [ 24, 26- 29].
Indeed, to decipher the complexity of the immune mechanisms and their underlying genetic control, immunogenomic approaches [ 13] are needed in combination with structural genomics approaches.
